ArticleBMC nephrology2025
Association of sleep habits with Alpha-MSH levels in patients with chronic kidney disease.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOur study aims to compare Alpha-MSH (α-MSH) levels and their relationship with sleep state in cases with and without chronic kidney disease (CKD). MATERIAL AND
methodsWe included CKD-diagnosed patients and a control group in this study. We assessed α-MSH, serum creatinine, and albumin levels in CKD-diagnosed patients and performed the Epworth sleepiness scale (ESS).
resultsA total of 155 people (56 controls, 84 CKD who did not need renal replacement therapy (CKD-without HD), and 15 under chronic hemodialysis (HD) therapy) were included in the study. ESS resulted in "sleepy" in 46.7% of HD, 33.3% in non-RRT CKD, and 19.6% in the control group. Sleepiness was statistically higher in the whole CKD (non-RRT and HD) group compared with the healthy group (p = 0.004). Pathologic ESS results had a positive correlation with the CKD stage and body mass index (BMI) in patients among the non-RRT CKD group. The most influential factors were BMI and eGFR. Considering all the patients, α -MSH results were highest in the control group and higher in the non-RRT group than in the HD group. Multivariate analysis revealed that the most significant factors were BMI and eGFR for pathologic ESS results.
conclusionsα-MSH levels in patients who diagnosed with CKD were lower than in the healthy group. The anti-inflammatory and sleep functions of α-MSH must be researched extensively. CKD patients with low eGFR and high BMI are at risk for sleepiness. In this group, special evaluation should be made in terms of sleep disorders.
trial registrationThe research had done with following permissions in Türkiye.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.